|Bid||69.44 x 100|
|Ask||69.60 x 100|
|Day's Range||68.08 - 69.59|
|52 Week Range||57.68 - 94.79|
|PE Ratio (TTM)||-90.92|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||86.78|
Fitbit Inc (NYSE:FIT) stock has finally broken out. Fitbit stock traded mostly between $5 and $6 after plunging. InvestorPlace columnist Larry Ramer argued the product would give a boost to FIT stock, and he may be right.
DexCom, Inc. , the leader in continuous glucose monitoring , announced today the availability of a public API, empowering third-party developers to connect patient-authorized CGM data into a broad range of software applications.
Fitbit Inc (NYSE:FIT) got a nice boost when it finally announced its Ionic smartwatch at the end of August. With the ability to see their blood glucose levels on their wrist, in real time, the new Fitbit smartwatch will go beyond fitness to offer people suffering from diabetes a real reason to buy. Last week, Fitbit announced it was partnering with Dexcom, the leading manufacturing of continuous glucose monitoring (CGM) devices.